Hormonal contraception in women at risk of vascular and metabolic disorders: Guidelines of the French Society of Endocrinology

Annales d'Endocrinologie

Volumn 73, Issue 5, 2012, Pages 469-487

  Gourdy, Pierre ^a   Bachelot, Anne ^b   Catteau Jonard, Sophie ^c   Chabbert Buffet, Nathalie ^d   Christin Maître, Sophie ^d   Conard, Jacqueline ^e   Fredenrich, Alexandre ^f   Gompel, Anne ^g   Lamiche Lorenzini, Françoise ^a   Moreau, Caroline ^h   Plu Bureau, Geneviève ^g   Vambergue, Anne ⁱ   Vergès, Bruno ^j   Kerlan, Véronique ^k  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIV LILLE   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e HÔTEL DIEU   (France)

^f PASTEUR HOSPITAL   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j DIJON UNIVERSITY HOSPITAL   (France)

^k UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BELANETTE; CARBAMAZEPINE; CARLIN; CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIENOGEST PLUS ESTRADIOL VALERATE; DROSPIRENONE PLUS ETHINYLESTRADIOL; EFEZIAL; ESTRADIOL PLUS NOMEGESTROL ACETATE; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; EVANECIA; EVEPAR; FELIXITA; JASMINELLE; LEELOO; LEVONORGESTREL; LUDEAL; LUMALIA; MELODIA; MINERVA; MINESSE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PACILIA; PERLEANE; TRIAFEMI; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIKIALE;

ARTERIAL THROMBOEMBOLISM; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FRANCE; HORMONAL CONTRACEPTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTRAUTERINE CONTRACEPTIVE DEVICE; LIPID METABOLISM; MEDICAL SOCIETY; METABOLIC DISORDER; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PREGNANCY DIABETES MELLITUS; PROTHROMBIN TIME; SEXUAL BEHAVIOR; SMOKING; TREATMENT CONTRAINDICATION; TREND STUDY; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

CARDIOVASCULAR DISEASES; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, HORMONAL; DIABETES MELLITUS; ENDOCRINOLOGY; ESTROGENS; FEMALE; FRANCE; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; METABOLIC DISEASES; OBESITY; PREGNANCY; PROGESTINS; RISK FACTORS; SOCIETIES, MEDICAL; THROMBOEMBOLISM;

EID: 84868254532     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2012.09.001     Document Type: Article

References (129)

1. Moreau C., Lydie N., Warzwaski J., Bajos N. Activité sexuelle, infections sexuellement transmissibles, contraception 2008, INPES. Baromètre Santé 2005, Saint-Denis, France.
2. WHO Medical eligibility criteria for contraceptive use. Fourth edition, 2009. A WHO family planning cornerstone 2009, World Health Organization, Geneva.
3. Centers for disease control and prevention. US. medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization medical eligibility criteria for contraceptive use, 4th edition. MMWR Recomm Rep 2010:1-86 p.
4. Leridon H., Oustry P., Bajos N., Cocon E.L.G. La medicalisation croissante de la contraception en France. Popul Soc 2002, 381:1-4.
5. Bajos N., Leridon H., Job-Spira N. Contraception et avortement en France dans les années 2000. Population 2004, 59(3-4):347-356.
6. Bajos N., Ferrand M., Gine A. De la contraception à l'avortement. Sociologie des grossesses non prévues 2002, I, editor, Paris.
7. Bajos N., Leridon H., Goulard H., Oustry P., Job-Spira N. Contraception: from accessibility to efficiency. Hum Reprod 2003, 18:994-999.
8. Bajos N., Moreau C., Leridon H., Ferrand M. Pourquoi le nombre d'avortements n'a-t-il pas baissé en France depuis 30ans ?. Popul Soc 2004, 407:1-4.
9. Vilain A. Les interruptions volontaires de grossesse en 2007. études et résultats. DREES 2009, 765:1-6.
10. Trussell J., Wynn L.L. Reducing unintended pregnancy in the United States. Contraception 2008, 77:1-5.
11. Moreau C., Trussell J., Desfreres J., Bajos N. Patterns of contraceptive use before and after an abortion: results from a nationally representative survey of women undergoing an abortion in France. Contraception 2010, 82:337-344.
12. Kost K., Singh S., Vaughan B., Trussell J., Bankole A. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception 2008, 77:10-21.
13. Moreau C., Trussell J., Rodriguez G., Bajos N., Bouyer J. Contraceptive failure rates in France: results from a population-based survey. Hum Reprod 2007, 22:2422-2427.
14. Moreau C., Bouyer J., Bajos N., Rodriguez G., Trussell J. Frequency of discontinuation of contraceptive use: results from a French population-based cohort. Hum Reprod 2009, 24:1387-1392.
15. Gallo M.F., Nanda K., Grimes D.A., Lopez L.M., Schulz K.F. 20μg versus>20μg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2011, 1:CD003989.
16. Rosenberg M.J., Waugh M.S., Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J Reprod Med 1995, 40:355-360.
17. Rosenberg M.J., Waugh M.S. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998, 179:577-582.
18. van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., Doggen C.J., Rosendaal F.R. The venous thrombotic risk of oral contraceptives, effects of estrogen dose and progestin type: results of the MEGA case-control study. BMJ 2009, 339:b2921.
19. Lidegaard O., Lokkegaard E., Svendsen A.L., Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009, 339:b2890.
20. Hannaford P.C. Epidemiology of the contraceptive pill and venous thromboembolism. Thromb Res 2011, 127(Suppl. 3):S30-S34.
21. van Hylckama Vlieg A., Middeldorp S. Hormone therapies and venous thromboembolism: where are we now?. J Thromb Haemost 2011, 9:257-266.
22. Kemmeren J.M., Algra A., Grobbee D.E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001, 323:131-134.
23. Parkin L., Sharples K., Hernandez R.K., Jick S.S. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011, 342:d2139.
24. Jick S.S., Hernandez R.K. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011, 342:d2151.
25. Kluft C., Lansink M. Effect of oral contraceptives on hemostasis variables. Thromb Haemost 1997, 78:315-326.
26. Rosing J., Middeldorp S., Curvers J., Christella M., Thomassen L.G., et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999, 354:2036-2040.
27. Middeldorp S., Meijers J.C., van den Ende A.E., van Enk A., Bouma B.N., et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000, 84:4-8.
28. Tans G., Curvers J., Middeldorp S., Thomassen M.C., Meijers J.C., et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000, 84:15-21.
29. Alhenc-Gelas M., Plu-Bureau G., Guillonneau S., Kirzin J.M., Aiach M., et al. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2004, 2:1594-1600.
30. van Vliet H.A., Bertina R.M., Dahm A.E., Rosendaal F.R., Rosing J., et al. Different effects of oral contraceptives containing different progestins on protein S and tissue factor pathway inhibitor. J Thromb Haemost 2008, 6:346-351.
31. Odlind V., Milsom I., Persson I., Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?. Acta Obstet Gynecol Scand 2002, 81:482-490.
32. Wiegratz I., Kutschera E., Lee J.H., Moore C., Mellinger U., et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003, 67:25-32.
33. van Vliet H.A., Frolich M., Christella M., Thomassen L.G., Doggen C.J., et al. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestins. Hum Reprod 2005, 20:563-568.
34. Rad M., Kluft C., Menard J., Burggraaf J., de Kam M.L., et al. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. Am J Obstet Gynecol 2006, 195:72-77.
35. van Vliet H.A., Rosendaal F.R., Rosing J., Helmerhorst F.M. Sex hormone-binding globulin: an adequate surrogate marker for venous thromboembolism in women using new hormonal contraceptives. Contraception 2009, 79:328-329. [author reply 329-30].
36. Christiansen S.C., Cannegieter S.C., Koster T., Vandenbroucke J.P., Rosendaal F.R. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005, 293:2352-2361.
37. Wu O., Robertson L., Twaddle S., Lowe G., Clark P., et al. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005, 131:80-90.
38. Jick S.S., Kaye J.A., Russmann S., Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35μg of ethinyl estradiol. Contraception 2006, 73:223-228.
39. Cole J.A., Norman H., Doherty M., Walker A.M. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007, 109:339-346.
40. Johnson J.V., Lowell J., Badger G.J., Rosing J., Tchaikovski S., et al. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet Gynecol 2008, 111:278-284.
41. Kluft C., Meijer P., LaGuardia K.D., Fisher A.C. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. Contraception 2008, 77:77-83.
42. Fleischer K., van Vliet H.A., Rosendaal F.R., Rosing J., Tchaikovski S., et al. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. Thromb Res 2009, 123:429-435.
43. van Vliet H.A., Rosendaal F.R., Fleischer K., Rosing J., Helmerhorst F.M. Effects of the contraceptive vaginal ring, the contraceptive transdermal patch and combined oral contraceptives on markers of hemostasis. Contraception 2010, 81:88-89. [author reply 89-90].
44. Bergendal A., Odlind V., Persson I., Kieler H. Limited knowledge on progestin-only contraception and risk of venous thromboembolism. Acta Obstet Gynecol Scand 2009, 88:261-266.
45. Lidegaard O., Kreiner S. Contraceptives and cerebral thrombosis: a five-year national case-control study. Contraception 2002, 65:197-205.
46. Heinemann L.A., Assmann A., DoMinh T., Garbe E. Oral progestin-only contraceptives and cardiovascular risk: results from the Transnational Study on oral contraceptives and the health of young women. Eur J Contracept Reprod Health Care 1999, 4:67-73.
47. Conard J., Plu-Bureau G., Bahi N., Horellou M.H., Pelissier C., et al. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004, 70:437-441.
48. World Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception Cardiovascular disease and use of oral and injectable progestin-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception 1998, 57:315-324.
49. van Hylckama Vlieg A., Helmerhorst F.M., Rosendaal F.R. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010, 30:2297-2300.
50. Stampfer M.J., Willett W.C., Colditz G.A., Speizer F.E., Hennekens C.H. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988, 319:1313-1317.
51. Shufelt C.L., Bairey Merz C.N. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009, 53:221-231.
52. Stefanick M.L., Prentice R.L., Anderson G., Gass M., Manson J.E., et al. Reanalysis of the Women's Health Initiative oral contraceptive data reveals no evidence of delayed cardiovascular benefit. Fertil Steril 2005, 83:853-854.
53. Dunn N., Thorogood M., Faragher B., de Caestecker L., MacDonald T.M., et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999, 318:1579-1583.
54. Tanis B.C., van den Bosch M.A., Kemmeren J.M., Cats V.M., Helmerhorst F.M., et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001, 345:1787-1793.
55. World Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997, 349:1202-1209.
56. Margolis K.L., Adami H.O., Luo J., Ye W., Weiderpass E. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 2007, 88:310-316.
57. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ 1993, 306:956-963.
58. Tzourio C., Tehindrazanarivelo A., Iglesias S., Alperovitch A., Chedru F., et al. Case-control study of migraine and risk of ischemic stroke in young women. BMJ 1995, 310:830-833.
59. Petitti D.B., Siscovick D.S., Sidney S., Schwartz S.M., Quesenberry C.P., et al. Norplant implants and cardiovascular disease. Contraception 1998, 57:361-362.
60. Chakhtoura Z., Canonico M., Gompel A., Thalabard J.C., Scarabin P.Y., et al. Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke 2009, 40:1059-1062.
61. Rosenberg L., Palmer J.R., Rao R.S., Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 2001, 161:1065-1070.
62. Thorogood M., Mann J., Murphy M., Vessey M. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. Br J Obstet Gynaecol 1991, 98:1245-1253.
63. Chakhtoura Z., Canonico M., Gompel A., Scarabin P.Y., Plu-Bureau G. Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis. J Clin Endocrinol Metab 2011, 96:1169-1174.
64. Chabbert-Buffet N., Amoura Z., Scarabin P.Y., Frances C., Levy D.P., et al. Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients. Contraception 2011, 83:229-237.
65. Plu-Bureau G., Horellou M.H., Gompel A., Conard J. Hormonal contraception and risk of venous thromboembolism: When to ask for an assessment of hemostasis? Which parameters?. Gynecol Obstet Fertil 2008, 36:448-454.
66. Lobo R.A., Skinner J.B., Lippman J.S., Cirillo S.J. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertil Steril 1996, 65:1100-1109.
67. LaRosa J.C. Effects of oral contraceptives on circulating lipids and lipoproteins: maximizing benefit, minimizing risk. Int J Fertil 1989, 34(Suppl.):71-84.
68. Sitruk-Ware R., Plu-Bureau G., Menard J., Conard J., Kumar S., et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab 2007, 92:2074-2079.
69. Burkman R.T. Transdermal hormonal contraception: benefits and risks. Am J Obstet Gynecol 2007, 197. 134e131-6.
70. Seibert C., Barbouche E., Fagan J., Myint E., Wetterneck T., et al. Prescribing oral contraceptives for women older than 35years of age. Ann Intern Med 2003, 138:54-64.
71. Anaes. Recommandations pour la pratique clinique. Stratégies de choix des méthodes contraceptives chez la femme. Anaes-Afssaps-Inpes. Service des recommandations professionnelles de l'Anaes 2004.
72. Godet-Thobie H., Vernay M., Noukpoape A., Salanave B., Malon A., et al. Niveau tensionnel moyen et prévalence de l'hypertension artérielle chez les adultes de 18 à 74ans, ENNS 2006-2007. BEH 2008, 49-50:478-483.
73. Goldstein L.B., Bushnell C.D., Adams R.J., Appel L.J., Braun L.T., et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010, 42:517-584.
74. Chasan-Taber L., Willett W.C., Manson J.E., Spiegelman D., Hunter D.J., et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996, 94:483-489.
75. Kriplani A., Periyasamy A.J., Agarwal N., Kulshrestha V., Kumar A., et al. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception 2010, 82:139-146.
76. Bouchard P. Chlormadinone acetate (CMA) in oral contraception-a new opportunity. Eur J Contracept Reprod Health Care 2005, 10(Suppl. 1):7-11.
77. Chan W.S., Ray J., Wai E.K., Ginsburg S., Hannah M.E., et al. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med 2004, 164:741-747.
78. Baillargeon J.P., McClish D.K., Essah P.A., Nestler J.E. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005, 90:3863-3870.
79. Curtis K.M., Jamieson D.J., Peterson H.B., Marchbanks P.A. Adaptation of the World Health Organization's medical eligibility criteria for contraceptive use for use in the United States. Contraception 2010, 82:3-9.
80. Fruzzetti F., Ricci C., Fioretti P. Hemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception 1994, 49:579-592.
81. Rosenberg M.J., Waugh M.S., Stevens C.M. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol 1996, 174:628-632.
82. Gillum L.A., Mamidipudi S.K., Johnston S.C. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 2000, 284:72-78.
83. Nightingale A.L., Lawrenson R.A., Simpson E.L., Williams T.J., MacRae K.D., et al. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000, 5:265-274.
84. Lawson D.H., Davidson J.F., Jick H. Oral contraceptive use and venous thromboembolism: absence of an effect of smoking. Br Med J 1977, 2:729-730.
85. Bajos N., Wellings K., Laborde C., Moreau C. Sexuality and obesity, a gender perspective: results from French national random probability survey of sexual behaviours. BMJ 2010, 340:c2573.
86. World Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995, 346:1582-1588.
87. Lidegaard O., Edstrom B., Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception 1998, 57:291-301.
88. World Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995, 346:1575-1582.
89. Pomp E.R., le Cessie S., Rosendaal F.R., Doggen C.J. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007, 139:289-296.
90. Sidney S., Petitti D.B., Soff G.A., Cundiff D.L., Tolan K.K., et al. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 2004, 70:3-10.
91. Grimes D.A., Shields W.C. Family planning for obese women: challenges and opportunities. Contraception 2005, 72:1-4.
92. Trussell J., Schwarz E.B., Guthrie K. Obesity and oral contraceptive pill failure. Contraception 2009, 79:334-338.
93. Holt V.L., Cushing-Haugen K.L., Daling J.R. Body weight and risk of oral contraceptive failure. Obstet Gynecol 2002, 99:820-827.
94. Holt V.L., Scholes D., Wicklund K.G., Cushing-Haugen K.L., Daling J.R. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005, 105:46-52.
95. Lopez L.M., Grimes D.A., Chen-Mok M., Westhoff C., Edelman A., et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2010, 7:CD008452.
96. Zieman M., Guillebaud J., Weisberg E., Shangold G.A., Fisher A.C., et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002, 77:S13-S18.
97. Huber J., Wenzl R. Pharmacokinetics of implanon. An integrated analysis. Contraception 1998, 58:85S-90S.
98. Glasier A., Cameron S.T., Blithe D., Scherrer B., Mathe H., et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 2011, 84:363-367.
99. Gerrits E.G., Ceulemans R., van Hee R., Hendrickx L., Totte E. Contraceptive treatment after biliopancreatic diversion needs consensus. Obes Surg 2003, 13:378-382.
100. Andersen A.N., Lebech P.E., Sorensen T.I., Borggaard B. Sex hormone levels and intestinal absorption of estradiol and D-norgestrel in women following bypass surgery for morbid obesity. Int J Obes (Lond) 1982, 6:91-96.
101. Victor A., Odlind V., Kral J.G. Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of jejunoileal bypass. Gastroenterol Clin North Am 1987, 16:483-491.
102. Croft J.B., Freedman D.S., Cresanta J.L., Srinivasan S.R., Burke G.L., et al. Adverse influences of alcohol, smoking, and oral contraceptive use on cardiovascular risk factors during transition to adulthood. Am J Epidemiol 1987, 126:202-213.
103. Simon D., Senan C., Garnier P., Saint-Paul M., Garat E., et al. Effects of oral contraceptives on carbohydrate and lipid metabolisms in a healthy population: the Telecom study. Am J Obstet Gynecol 1990, 163:382-387.
104. Lopez L.M., Grimes D.A., Schulz K.F. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2007, 2:CD006133.
105. Kjos S.L., Gregory K., Henry O.A., Collins C. Evaluation of routine diabetes and lipid screening after age 35 in candidates for or current users of oral contraceptives. Obstet Gynecol 1993, 82:925-930.
106. Oelkers W., Foidart J.M., Dombrovicz N., Welter A., Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestin, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995, 80:1816-1821.
107. WHO Special Programme of Research, Development and Research training in Human Reproduction. Task force on oral contraceptives. A randomized double-blind study of the effects of two low-dose combined oral contraceptives on biochemical aspects. Report from a seven-centred study. Contraception 1985;32:223-6.
108. Yu A.F., Wu S.X., Liu J.L., Liu A.R., Li J.Z., et al. Metabolic changes in women using a long-acting monthly oral contraceptive and return of ovulation on discontinuation. Contraception 1988, 37:517-528.
109. Porkka K.V., Erkkola R., Taimela S., Raitakari O.T., Dahlen G.H., et al. Influence of oral contraceptive use on lipoprotein (a) and other coronary heart disease risk factors. Ann Med 1995, 27:193-198.
110. Kim C., Siscovick D.S., Sidney S., Lewis C.E., Kiefe C.I., et al. Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA Study. Coronary artery risk development in young adults. Diabetes Care 2002, 25:1027-1032.
111. Crook D., Godsland I. Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism. Contraception 1998, 57:189-201.
112. Cagnacci A., Ferrari S., Tirelli A., Zanin R., Volpe A. Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study. Contraception 2009, 80:34-39.
113. Rimm E.B., Manson J.E., Stampfer M.J., Colditz G.A., Willett W.C., et al. Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 1992, 35:967-972.
114. Chasan-Taber L., Willett W.C., Stampfer M.J., Hunter D.J., Colditz G.A., et al. A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 1997, 20:330-335.
115. Rosenthal A.D., Shu X.O., Jin F., Yang G., Elasy T.A., et al. Oral contraceptive use and risk of diabetes among Chinese women. Contraception 2004, 69:251-257.
116. Bellamy L., Casas J.P., Hingorani A.D., Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009, 373:1773-1779.
117. Beydoun H.A., Beydoun M.A., Tamim H. How does gestational diabetes affect postpartum contraception in nondiabetic primiparous women?. Contraception 2009, 79:290-296.
118. Skouby S.O., Kuhl C., Molsted-Pedersen L., Petersen K., Christensen M.S. Triphasic oral contraception: metabolic effects in normal women and those with previous gestational diabetes. Am J Obstet Gynecol 1985, 153:495-500.
119. Kjos S.L., Peters R.K., Xiang A., Thomas D., Schaefer U., et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998, 280:533-538.
120. Baptiste-Roberts K., Barone B.B., Gary T.L., Golden S.H., Wilson L.M., et al. Risk factors for type 2 diabetes among women with gestational diabetes: a systematic review. Am J Med 2009, 122. 207e204-14.
121. Nelson A.L., Le M.H., Musherraf Z., Vanberckelaer A. Intermediate-term glucose tolerance in women with a history of gestational diabetes: natural history and potential associations with breastfeeding and contraception. Am J Obstet Gynecol 2008, 198. 699e691-7 [discussion 699e697-8].
122. Visser J., Snel M., Van Vliet H.A. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2. Cochrane Database Syst Rev 2006, 4:CD003990.
123. Grigoryan O.R., Grodnitskaya E.E., Andreeva E.N., Shestakova M.V., Melnichenko G.A., et al. Contraception in perimenopausal women with diabetes mellitus. Gynecol Endocrinol 2006, 22:198-206.
124. Garg S.K., Chase H.P., Marshall G., Hoops S.L., Holmes D.L., et al. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 1994, 271:1099-1102.
125. Klein B.E., Klein R., Moss S.E. Exogenous estrogen exposures and changes in diabetic retinopathy. The Wisconsin Epidemiologic Study of diabetic retinopathy. Diabetes Care 1999, 22:1984-1987.
126. Ahmed S.B., Hovind P., Parving H.H., Rossing P., Price D.A., et al. Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 2005, 28:1988-1994.
127. World Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception Ischemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996, 348:498-505.
128. Petitti D.B., Sidney S., Bernstein A., Wolf S., Quesenberry C., et al. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996, 335:8-15.
129. Petersen K.R. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Dan Med Bull 2002, 49:43-60.